Compare United States Oil ETF (USO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Oil ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? United States Oil ETF trades at $146.51 (market cap $1.83B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 70× United States Oil ETF's market cap, and United States Oil ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Oil ETF for 21 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| USO | VRTX | |
|---|---|---|
Market Cap | $1.83B | $128.16B |
Volume | 3,073,172 | 806,603 |
52-Week High | $161.86 | $557.96 |
52-Week Low | $66.17 | $407.37 |
Typical Hold Time | 21 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USO trades at $143.91, down 0.7% amid mixed oil market signals. Technical indicators show neutral momentum with bearish moving averages, while geopolitical tensions and supply dynamics dominate sentiment. The stock faces resistance at $145 and support at $142, with recent news highlighting Middle East conflicts and OPEC+ production decisions affecting energy sector volatility.
The outlook remains uncertain with competing pressures from geopolitical risks and coordinated reserve releases. Investment opportunities exist if supply disruptions persist, but risks include potential price stabilization from G-7 interventions and broader market volatility. Current technical positioning suggests cautious near-term trading with key levels defining directional bias.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
